Twist Bioscience Corp — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Twist Bioscience Corp filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q1 | 2026 | Dec 31, 2025 | ($30.51M) | Feb 26, 2026 |
| Q3 | 2025 | Jun 30, 2025 | $20.39M | Aug 4, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($39.33M) | May 5, 2025 |
| Q1 | 2026 | Dec 31, 2024 | ($31.59M) | Feb 26, 2026 |
| Q3 | 2025 | Jun 30, 2024 | ($85.57M) | Aug 4, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($45.49M) | May 5, 2025 |
| Q1 | 2025 | Dec 31, 2023 | ($43.01M) | Feb 3, 2025 |
| Q3 | 2024 | Jun 30, 2023 | ($57.40M) | Aug 2, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($59.16M) | May 2, 2024 |
| Q1 | 2024 | Dec 31, 2022 | ($41.82M) | Feb 2, 2024 |
| Q3 | 2023 | Jun 30, 2022 | ($60.52M) | Aug 7, 2023 |
| Q2 | 2023 | Mar 31, 2022 | ($60.67M) | May 8, 2023 |
| Q1 | 2023 | Dec 31, 2021 | ($45.56M) | Feb 7, 2023 |
| Q3 | 2022 | Jun 30, 2021 | ($40.04M) | Aug 8, 2022 |
| Q2 | 2022 | Mar 31, 2021 | ($37.92M) | May 6, 2022 |
| Q1 | 2022 | Dec 31, 2020 | ($32.90M) | Feb 9, 2022 |
| Q3 | 2021 | Jun 30, 2020 | ($28.21M) | Aug 9, 2021 |
| Q2 | 2021 | Mar 31, 2020 | ($31.77M) | May 7, 2021 |
| Q1 | 2021 | Dec 31, 2019 | ($55.64M) | Feb 9, 2021 |
| Q3 | 2020 | Jun 30, 2019 | ($27.92M) | Aug 12, 2020 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q1 | 2026 | Dec 31, 2025 | ($32.90M) | Feb 26, 2026 |
| Q3 | 2025 | Jun 30, 2025 | ($30.12M) | Aug 4, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($41.56M) | May 5, 2025 |
| Q1 | 2026 | Dec 31, 2024 | ($34.64M) | Feb 26, 2026 |
| Q3 | 2025 | Jun 30, 2024 | ($88.92M) | Aug 4, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($48.89M) | May 5, 2025 |
| Q1 | 2025 | Dec 31, 2023 | ($46.98M) | Feb 3, 2025 |
| Q3 | 2024 | Jun 30, 2023 | ($60.78M) | Aug 2, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($61.64M) | May 2, 2024 |
| Q1 | 2024 | Dec 31, 2022 | ($44.63M) | Feb 2, 2024 |
| Q3 | 2023 | Jun 30, 2022 | ($61.16M) | Aug 7, 2023 |
| Q2 | 2023 | Mar 31, 2022 | ($60.80M) | May 8, 2023 |
| Q1 | 2023 | Dec 31, 2021 | ($55.94M) | Feb 7, 2023 |
| Q3 | 2022 | Jun 30, 2021 | ($42.12M) | Aug 8, 2022 |
| Q2 | 2022 | Mar 31, 2021 | ($38.00M) | May 6, 2022 |
| Q1 | 2022 | Dec 31, 2020 | ($32.79M) | Feb 9, 2022 |
| Q3 | 2021 | Jun 30, 2020 | ($28.20M) | Aug 9, 2021 |
| Q2 | 2021 | Mar 31, 2020 | ($32.09M) | May 7, 2021 |
| Q1 | 2021 | Dec 31, 2019 | ($55.83M) | Feb 9, 2021 |
| Q3 | 2020 | Jun 30, 2019 | ($28.12M) | Aug 12, 2020 |